If you liked this article you might like

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too
AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers
Nasdaq Tumbles as Tech Takes a Turn Lower